8-K filed Apr 30, 2026 at 07:17 ET
Baxter reported Q1 2026 adjusted diluted EPS of $0.36, beating the $0.31 consensus by 16.1%, on revenue of $2.70B vs. $2.62B consensus (+3.1% beat). However, organic sales declined 1% YoY, adjusted EPS fell 35% YoY, and the company merely reiterated its full-year 2026 outlook of flat organic growth and adjusted EPS of $1.85-$2.05. The combination of a headline beat with deteriorating underlying trends (declining organic revenue, tariff headwinds, ongoing Novum IQ pump hold) makes this a mixed filing.